Prognostic Performance of a Chemogram in Patients With Bladder Cancer.

Launched by LILLE CATHOLIC UNIVERSITY · May 6, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to personalize treatment for patients with bladder cancer, particularly those with intermediate-grade superficial bladder cancer and infiltrating bladder cancer. The focus is on using a test called a chemogram to understand how effective chemotherapy might be for each individual patient. While chemotherapy is a standard treatment, the study aims to tailor it to the unique characteristics of each person's cancer, which could help reduce the chances of the cancer returning after treatment.

To be eligible for this trial, participants should be adults who have been diagnosed with bladder cancer and are likely to receive chemotherapy. They must also be part of a social security healthcare plan. The trial is currently recruiting and welcomes all genders, specifically targeting those aged 65 to 74. Participants will have the opportunity to contribute to important research that may improve treatment options for bladder cancer in the future. It's important to note that individuals who are pregnant, breastfeeding, or have certain medical conditions may not be able to participate.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Major patient
• • Patient with suspected bladder cancer likely to be treated with chemotherapy
• • Patient affiliated to a social security scheme
• Exclusion Criteria:
• • Insufficient tumor volume
• • Patient under guardianship
• • Pregnant or breast-feeding women
• • Patient opposed to participation in the study